Optica Spectrum Disorder
Amgen’s Uplizna Achieves Success in Phase 3 Trial for Immunoglobulin G4-Related Disease (IgG4-RD)
Amgen, Uplizna, IgG4-RD, Phase 3 Trial, Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD)
Actionable Insights Powered by AI
Amgen, Uplizna, IgG4-RD, Phase 3 Trial, Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD)